Atossa Therapeutics Inc

Atossa Therapeutics insider buys reveal confidence amid volatility: discover why executives are buying shares and what it means for investors.

Insider buying spikes at Atossa, with top execs snapping up 40k shares ahead of May 19 data—signaling confidence in a potentially undervalued, future‑boosting pipeline.

CEO Steven Quay’s recent zero‑cost RSU purchase fuels optimism about Atossa Therapeutics’ upside potential, despite a volatile stock and low liquidity.

Atossa Therapeutics’ CEO buys 325k shares and 950k options, boosting insider confidence despite a 52‑week low, signaling potential upside as the company aims for a clinical breakthrough.